PHA 2005 (3167/6Z/US) PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of John P. McKearn et al. Art Unit 1617 Serial No. 09/857,994 Filed October 5, 2001 Confirmation No. 4028

For METHOD OF USING AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA

February 18, 2004

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VIRGINIA 22313-1450

SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

In preparation of this Supplemental Information Disclosure Statement, Applicants determined that approximately 1,000 references were cited in the application. In an effort to reduce the burden on the Office, each reference was briefly reviewed by an attorney. This review eliminated any reference that was determined to be irrelevant or merely cumulative. If the Office would like a copy of the eliminated references, they can be provided at the Office's request.

A check in the amount of \$180.00 is enclosed to cover the fee specified in 37 CFR §1.17(p) for submission of this

Supplemental Information Disclosure Statement. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

Respectfully submitted,

Kethryn J. Doty, Reg. No. 40,593 SENNIGER, POWERS, LEAVITT & ROEDEL One Metropolitan Square, 16th Floor

St. Louis, Missouri 63102

(314) 231-5400

KJD/msc
*Enclosures

Mail Stop AF Express Mail Label No. EV 416453092 US

কিপিউB	A8A			Complete if Known			
rtn 4 o 2004	ື່ອ SUPPLEN	/ENT	·AL	Application Number	09/857,994		
FEB 1 8 2004	SUPPLEN IF STEMATION SATEMENT BY	DISC	LOSURE	Filing Date	October 5, 2001		
RADEMASS	MIEWIENI D	1 AP	PLICANT	Confirmation Number	4028		
	e as many shee	ts as	necessary)	First Named Inventor	John P. McKearn et al.		
				Group Art Unit	1617		
				Examiner Name	San-ming R. Hui		
Sheet	1	of	2	Attorney Docket No.	PHA 2005 (3167/6Z/US)		

			U.	S. PATENI	DOCUMENTS	}			
			U.S. Patent Docu	ument	Name of Patentee or Applicant of Cited Document		Date of Publication of Cited Document MM-DD-YYYY		
Examiner Initials*	Cite No. ¹		Number	Kind Code ² (if known)					
	282.	6,077,8	50		Carter et al.		06-20-2000		
	283.	6,087,3	92		Reiter	Reiter			
	284.	6,110,9	64		Robinson	Robinson		08-29-2000	
	285.	6,114,3	61		Robinson et al. Reiter McClure et al.		09-05-2000 12-05-2000 04-10-2001		
	286.	6,156,7	98						
	287.	6,214,8	70	B1					
	288.	6,277,8	78	B1	Nakao et al.		08-21-2001		
	289.	6,294,5	558	B1	Ando et al.		09-25-2001		
			FOR	EIGN PATE	NT DOCUMEN	ITS			
		F	oreign Patent Do	cument					
Examiner Initials*	Cite No. ¹	Office	Number⁴	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document		Date of Publication of Cited Document MM-DD-YYYY	Τ ⁶	
	290.	290. EP 1 081 137 A1 Pfizer Products Inc.			03-07-2001				
	291.	EP	1 088 550	A1	Pfizer Products Inc.		04-04-2001		
	292.	EP	1 104 759	A1	Pfizer Products Inc.		06-06-2001		
Examiner					Date				

Examiner Date Signature Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

PTP/EB/08A						Complete if Known					
SUPPLEMENTAL B 18 21NFQRMATION DISCLOSURE							11		09/857,994 October 5, 2001		
											S.
TRADEUS E	as man	y shee	ets as	necessary)	١	Fi					
						G	roup Art Unit	1617			
						\vdash	xaminer Name	San-	ming R. Hui		
Sheet	Sheet 2 of 2						ttorney Docket No.	+	2005 (3167/6Z/US	—)	
		•		· · · · · · · · · · · · · · · · · · ·		<u> </u>				_	
	293.	EP	1 10)4 760	A1		Pfizer Products Inc.		06-06-2001	L	
	294.	EP	1 13	34 215	A1		Pfizer Products Inc.		09-19-2001		
	295.	EP	1 13	38 680	A1		Pfizer Products Inc.		10-04-2001	Ī	
	296.	wo	97/4	18685	A1		Glaxo Group Limited		12-24-1997	Π	
	297.	8. WO 98/30566 0. WO 98/47890 0. WO 00/09485		03516 A1			Pfizer Inc.		01-29-1998	Γ	
	298.			30566	A1 A1		Pfizer Inc.		07-16-1998		
	299.			17890			G.D. Searle & Co.		10-29-1998	Π	
	300.			A1 _		Pfizer Products Inc.		02-24-2000			
-	301.			A1	A1 Pfizer Products Inc.			02-24-2000	Γ		
	302.	wo	WO 00/73294 A2		A2		Pfizer Products Inc.		12-07-2000	Ī	
	303.	wo	01/	12611	A1		Pfizer Products Inc.		02-22-2001		
	304.	wo	01/4	10216	A1		Pfizer Products Inc.	****	06-07-2001		
		ОТ	HER	ART - NON	PATI	ENT	LITERATURE DOC	UMEN	TS		
Examiner Initials*	Cite No.1			ok, magazine, jo	ournal,	seria	L LETTERS), title of the articl al, symposium, catalog, etc.) ner, city and/or country where	date, pa	ge(s), volume-issue	Т	

	 	<u></u>
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

FEE TRANSMITTAL

Art Unit 1617

February 18, 2004

Date

FB 18 7 Population Number 09/857,994

Filding Date October 5, 2001

Confirmation No. 4028

Driventor(s) John P. McKearn et al.

Attorney Docket Number PHA 2005 (3167/6Z/US)

		METHOD OF PAIMENT
1.	[]	The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345.
	[X]	The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 to Deposit Account No. 19-1345.
	[]	Applicant claims small entity status.
2.	[X]	Check Enclosed. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.
		FEE CALCULATION
1.	[]	BASIC FILING FEE Subtotal (1) \$(Type:)
2.	[]	EXTRA CLAIM FEES Subtotal (2) \$
		Total Claims Independent Claims Multiple Dependent Claims
3.	[X]	ADDITIONAL FEES Subtotal (3) \$ 180.00
,		<pre>[] Surcharge - late filing fee or oath [] Surcharge - late provisional filing fee or cover sheet [] Extension for reply within month [] Notice of Appeal [] Filing a Brief in Support of an appeal [] Request for ex parte Reexamination [] Petitions to the Commissioner [X] Submission of Information Disclosure Statement [] Recording each patent assignment per property [] Request for Continued Examination [] Other:</pre>
TOTA	L AMO	UNT OF PAYMENT \$ 280.00

KJD/CDS/msc

Express Mail Label No. EV 416453092 US

Reg. No. 40